ArticleOncology letters2025
Genomic and clinical‑pathological features of mucinous cystadenocarcinoma of the breast with HER2 amplification: A case report.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucinous cystadenocarcinoma (MCA) of the breast is a rare, invasive carcinoma that resembles pancreatobiliary or ovarian MCA in terms of histological appearance. Most cases of MCA of the breast are negative for the estrogen receptor, progesterone receptor and ERBB2 (HER2). To the best of our knowledge, only five reports of HER2-positive MCA cases have been reported in the English language, and no reports focusing on the molecular characteristics of HER2-positive MCAs have been published. In the present study, a rare case of a 64-year-old woman with HER2-positive MCA who underwent long-term follow-up without recurrence or distant metastasis is reported. In addition, a detailed analysis of the genomic characteristics of the tumor is provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.